ReviewJournal of translational medicine2025
Unlocking the benefits of aerobic exercise for MAFLD: a comprehensive mechanistic analysis.
Review in Journal of translational medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Exercise-Induced Hepatic Mitochondrial Reprogramming Across Muscle-Gut-Thyroid Axes in MASLD/MASH.International journal of molecular sciences · 2026Review
- Exercise as a Molecular Therapeutic Tool in MASLD: From Signaling Pathways to Clinical Translation-A Narrative Review.Biomedicines · 2026Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundMetabolic dysfunction-associated fatty liver disease (MAFLD), characterized by abnormal accumulation of triglycerides (TG) and cholesterol in hepatocytes, is a globally prevalent chronic liver disease with a rising incidence that poses a severe threat to human health. In the absence of effective targeted drugs and long-term prognostic interventions for MAFLD, aerobic exercise, as a safe and accessible non-pharmacological strategy, is widely recognized to slow MAFLD progression. However, a systematic summary of its mechanisms in ameliorating MAFLD remains insufficient. MAIN BODY: This review integrates recent high-quality PubMed studies and classic models (e.g., high-fat diet-induced C57BL/6J mice, HepG2 cells) to analyze aerobic exercise's therapeutic effects on MAFLD and underlying molecular mechanisms. Aerobic exercise regulates MAFLD via a multi-dimensional network. SESN family signaling regulates hepatic lipid metabolism, improves insulin resistance, enhances antioxidant capacity, and promotes lipophagy. miRNA-mediated regulation modulates lipogenic gene expression, insulin signaling, and fatty acid oxidation via exercise-induced changes in key miRNAs and their upstream regulators or downstream targets. AMPK-centered energy metabolism orchestrates fatty acid β-oxidation promotion and de-novo lipogenesis suppression through its related pathways. Other key pathways include inhibiting lipogenesis via exercise-induced IL-6, blocking hepatic inflammation through brown adipose-derived Nrg4, optimizing lipid droplet-mitochondria interaction by regulating PLIN5 and Mfn-2, and suppressing ferroptosis via activating antioxidant pathways. Notably, mechanisms initially validated in non-alcoholic fatty liver disease (NAFLD) are equally applicable to MAFLD, as both are characterized by core metabolic dysfunction.
conclusionAerobic exercise alleviates MAFLD progression by orchestrating a complex regulatory network involving energy metabolism, stress response, post-transcriptional modification, and inter-organ crosstalk. This review clarifies the key molecular targets and signaling pathways underlying aerobic exercise's therapeutic effects, providing a theoretical basis for exploring potential targeted interventions and guiding future drug development for MAFLD.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.